BRIDGEBIO PHARMA, INC.

Lobbying client · California · filed 2025 to 2026

Biotech company

$2,110,000 Reported spend

6 Filings counted

1 Firms hired

9 Bills named

Spend is reported income plus in-house expenses across 6 filings. 1 further filing on this record was restated by a later amendment and is left out of every total here. Everything on this page is grouped by the client's LDA id (57334), not by name.

Firms hired 1

BRIDGEBIO PHARMA, INC. $2,110,000 6 filings

Bills named in these filings 9

HR 1262
Mikaela Naylon Give Kids a Chance Act

5 filings
HR 1532
Scientific EXPERT Act of 2025

4 filings
S 822
Scientific EXPERT Act of 2025

4 filings
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

3 filings
HR 1414
Cameron’s Law

3 filings
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

1 filing
HR 4317
PBM Reform Act of 2025

1 filing
HR 7148
Consolidated Appropriations Act, 2026

1 filing
S 932
Give Kids a Chance Act of 2025

1 filing

Reported by year 2 years

2026 $920,000 2 filings
2025 $1,190,000 4 filings

Issues lobbied 1

Pharmacy 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 6
SENATE 6

Recent filings 7 total

Q2

BRIDGEBIO PHARMA, INC.

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $500,000 expenses · posted Jul 20, 2026

View → 4A

BRIDGEBIO PHARMA, INC.

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $280,000 expenses · posted Jul 17, 2026

View → Q1

BRIDGEBIO PHARMA, INC.

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $420,000 expenses · posted Apr 20, 2026

View → Q4

BRIDGEBIO PHARMA, INC. Amended

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $270,000 expenses · posted Jan 20, 2026

View → Q3

BRIDGEBIO PHARMA, INC.

3rd Quarter (July 1 - Sep 30) 2025 · House · Senate · $270,000 expenses · posted Oct 20, 2025

View → Q2

BRIDGEBIO PHARMA, INC.

2nd Quarter (Apr 1 - June 30) 2025 · House · Senate · $320,000 expenses · posted Jul 17, 2025

View → Q1

BRIDGEBIO PHARMA, INC.

1st Quarter (Jan 1 - Mar 31) 2025 · House · Senate · $320,000 expenses · posted Apr 18, 2025

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.